1-3 of 3
Sara Ferrando-Martínez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b Dose Expansion Study Evaluating Safety, Preliminary Anti-Tumor Activity, and Accelerated T Cell Reconstitution with NT-I7 (Efineptakin Alfa), a Long-Acting Human IL-7, Administered Following Tisagenlecleucel in Subjects with Relapsed/Refractory Large B-Cell Lymphoma

Armin Ghobadi, L. Elizabeth Budde, Ahmed Galal, Kristina Stermer, Allison Bierly, Sara Ferrando-Martinez, Byung Ha Lee, John F. DiPersio
Journal: Blood
Blood (2022) 140 (Supplement 1): 10366–10367.
https://doi.org/10.1182/blood-2022-159504
Published: 2022
Journal Articles

Potential Synergy of TRAIL with CDK9 Inhibition in Selective Killing of HIV Infected Cell Lines and Primary CD4+ T Cells

David Kotlyar, MD, Constantinos Petrovas, PhD, Arik Cooper, PhD, David Ambrozak, MS, Christina Annunziata, MD PhD, Lidia Hernandez, PhD, Takuya Yamamoto, PhD, Sara Ferrando-Martinez, PhD, Joseph Casazza, MD PhD, Richard Koup, MD
Journal: Blood
Blood (2014) 124 (21): 4142.
https://doi.org/10.1182/blood.V124.21.4142.4142
Published: 2014
Journal Articles

CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection

Rodolfo Silva, Susan Moir, Lela Kardava, Karen Debell, Venkateswara R. Simhadri, Sara Ferrando-Martínez, Manuel Leal, José Peña, John E. Coligan, Francisco Borrego
Journal: Blood
Blood (2011) 117 (22): 5870–5880.
https://doi.org/10.1182/blood-2010-09-310318
Published: 2011
Includes: Supplemental data